A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the survival of patients treated with Litx™ versus
standard of care therapies in the treatment of unresectable hepatocellular carcinoma (HCC),
and to demonstrate the safety of Litx™ therapy.
Litx™ consists of a light-activated drug, talaporfin sodium (LS11, Light Sciences Oncology,
Bellevue, Washington), and a light generating device, composed of light-emitting diodes
(LEDs), that is energized by a power controller and percutaneously placed in the target
tissue inside the body.